Glazer Capital LLC’s Aimmune Therapeutics AIMT Stock Holding History

Glazer Capital LLC’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-150,000	Closed	-$5.17M	–	499
2020 Q3	$5.17M	Buy	+150,000	New	+$3.19M	0.25%	102

Glazer Capital LLC's AIMT Position: Q4 2020 in Review

Glazer Capital LLC sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 150,000 shares — an estimated $5.17M sold.

Glazer Capital LLC first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $5.17M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Glazer Capital LLC reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Glazer Capital LLC sold 150,000 Aimmune Therapeutics shares in Q4 2020, an estimated $5.17M.
Glazer Capital LLC first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Glazer Capital LLC's Aimmune Therapeutics position peaked at $5.17M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Glazer Capital LLC's 13F filing for Q4 2020, filed 16 Feb 2021.